{"id":95687,"date":"2025-06-26T12:40:08","date_gmt":"2025-06-26T12:40:08","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/iova-securities-lose-money-on-iovance-biotherapeutics-nasdaqiova-contact-bfa-law-about-the-pending-securities-fraud-class-action\/"},"modified":"2025-06-26T12:40:08","modified_gmt":"2025-06-26T12:40:08","slug":"iova-securities-lose-money-on-iovance-biotherapeutics-nasdaqiova-contact-bfa-law-about-the-pending-securities-fraud-class-action","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/iova-securities-lose-money-on-iovance-biotherapeutics-nasdaqiova-contact-bfa-law-about-the-pending-securities-fraud-class-action\/","title":{"rendered":"IOVA SECURITIES: Lose Money on Iovance Biotherapeutics (NASDAQ:IOVA)? Contact BFA Law about the Pending Securities Fraud Class Action"},"content":{"rendered":"
\n

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP<\/strong><\/a> announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws.<\/p>\n

If you invested in Iovance you are encouraged to obtain additional information by visiting <\/strong>https:\/\/www.bfalaw.com\/cases-investigations\/iovance-biotherapeutics-inc-class-action-lawsuit<\/strong><\/a>.<\/p>\n

Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities.\u00a0\u00a0 The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al.<\/em>, No. 25-cv-04177.<\/p>\n

Why was Iovance Sued for Securities Fraud?<\/strong><\/p>\n

Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company\u2019s authorized treatment centers (\u201cATCs\u201d).<\/p>\n

As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance\u2019s ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs.<\/p>\n

The Stock Declines as the Truth is Revealed<\/strong><\/p>\n

On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was \u201crevising full-year 2025 revenue guidance.\u201d The Company blamed \u201crecent launch dynamics,\u201d including slow \u201ctreatment timelines for new ATCs\u201d and \u201cthe variable pace at which ATCs began treating patients,\u201d which \u201cdiffers from center to center.\u201d Iovance also blamed the poor results on high \u201cpatient drop-off\u201d due to inadequate \u201cpatient selection\u201d for treatment.<\/p>\n

On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025.<\/p>\n

Click here if you suffered losses: <\/strong>https:\/\/www.bfalaw.com\/cases-investigations\/iovance-biotherapeutics-inc-class-action-lawsuit<\/strong><\/a>.<\/strong><\/p>\n

What Can You Do?<\/strong><\/p>\n

If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm.<\/p>\n

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n

Submit your information by visiting:<\/strong><\/p>\n

https:\/\/www.bfalaw.com\/cases-investigations\/iovance-biotherapeutics-inc-class-action-lawsuit<\/strong><\/a><\/p>\n

Or contact:
Ross Shikowitz
ross@bfalaw.com<\/a>
212-789-3619<\/p>\n

Why Bleichmar Fonti & Auld LLP?<\/strong><\/p>\n

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs\u2019 Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n

For more information about BFA and its attorneys, please visit https:\/\/www.bfalaw.com<\/a>.<\/p>\n

https:\/\/www.bfalaw.com\/cases-investigations\/iovance-biotherapeutics-inc-class-action-lawsuit<\/strong><\/a><\/p>\n

Attorney advertising. Past results do not guarantee future outcomes.<\/em><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain […]<\/p>\n","protected":false},"author":2,"featured_media":95688,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-95687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/95687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=95687"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/95687\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/95688"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=95687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=95687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=95687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}